Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
Ben Ho Park, M.D., Ph.D.
Professor of Oncology
Expertise: Breast Cancer, Medical Oncology
Research Interests: Using somatic cancer alterations as blood based biomarkers to guide breast cancer therapy
Request an Appointment
I live in Maryland
Request an appointment through My
I live outside of Maryland
I live outside of the United States
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Appointment Phone: 410-955-8964
401 N. Broadway
Baltimore, MD 21231 map
Ben Ho Park, M.D., Ph.D., is a professor of oncology at the Johns Hopkins University School of Medicine and associate director for Research Training and Education and associate director of the Hematology/Oncology Fellowship Training Program at the Johns Hopkins Kimmel Cancer Center.
Dr. Park is a medical oncologist specializing in breast cancer, and he leads a research program using genetic approaches for developing new diagnostics and therapies for breast cancer. More recently, his laboratory has been focused on developing circulating plasma tumor DNA for individualized therapies in early stage breast cancer.
Dr. Park received his M.D. and Ph.D. from the University of Pennsylvania and joined the faculty at Johns Hopkins in 2002.
- Professor of Oncology
- MD, University of Pennsylvania School of Medicine (1995)
- University of Pennsylvania School of Medicine / Internal Medicine (1998)
- American Board of Internal Medicine / Medical Oncology (2002, 2012)
Research & Publications
Clinical Trial Keywordsbreast cancer
Learn more about clinical trials at the Johns Hopkins Kimmel Cancer Center.
Selected PublicationsView all on Pubmed
Bachman KE,* Park BH,* Rhee I, Rajagopalan H, Herman JG, Baylin SB, Kinzler KW and Vogelstein B. The role of histone codes and DNA methylation in silencing tumor suppressor genes, Cancer Cell 3:89-95, 2003. *Contributed equally to this work.
Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi Y, Mohseni M, Wang G, Rosen DM, Denmeade SR, Higgins MJ, Vitolo MI, Bachman KE, Park BH. Knock in of mutant PIK3CA activates multiple oncogenic pathways. Proceedings of the National Academy of Science, U.S.A, Feb 24;106(8):2835-40, 2009.
Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir, K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, Cosgrove D, Cochran R, Jelovac D, Higgins MJ, Arena S, Hawkins L, Lauring J, Gross AL, Heaphy C, Hosokawa Y, Gabrielson E, Meeker A, Visvanathan K, Argani P, Bachman KE, Park BH. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cell, Proceedings of the National Academy of Science, U.S.A, Oct 25;108(43):17773-8, 2011.
Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, Zorzi J, Jeter SC, Oliver GR, Diehl F, Angenendt P, Huang P, Cope L, Argani P, Murphy KM, Bachman KE, Greshock J, Wolff AC, Park BH. Detection of tumor PIK3CA status in Metastatic Breast Cancer using Peripheral Blood and Implications for Targeted Therapy, Clinical Cancer Research, Jun 15;18(12):3462-9, 20
Beaver JA, Jelovac D, Balukrishna S, Cochran R, Croessmann S, Zabransky DJ, Wong HY, Toro PV, Cidado J, Blair BG, Chu D, Burns T, Higgins MJ, Stearns V, Jacobs L, Habibi M, Lange J, Hurley PJ, Lauring J, VanDenBerg D, Kessler J, Jeter S, Samuels M, Maar D, Cope L, Cimino-Mathews A, Argani P, Wolff AC* and Park BH*. Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer, Clinical Cancer Research, May 15;20(10):2643-50, 2014, *co-corresponding senior authors.